KROS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
-100.0%
367.0K
-4.7%
385.0K
-97.3%
14.3M
-21.5%
18.2M
Cost of Revenue
0
0
0
0
0
Gross Profit
0
-100.0%
367.0K
-4.7%
385.0K
-97.3%
14.3M
-21.5%
18.2M
Operating Expenses
30.9M
+17.9%
26.2M
-11.5%
29.7M
+0.0%
29.6M
-48.9%
58.0M
R&D
22.3M
+38.7%
16.1M
-10.1%
17.9M
-8.2%
19.5M
-55.1%
43.5M
SG&A
8.6M
-15.2%
10.1M
-13.6%
11.7M
+16.0%
10.1M
-30.1%
14.5M
Operating Income
-30937000
-19.6%
-25877000
+11.6%
-29270000
-90.3%
-15384000
+61.4%
-39817000
EBITDA
-30535000
-19.9%
-25474000
+11.8%
-28870000
-92.6%
-14989000
+62.0%
-39447000
Net Income
-28710000
-21.1%
-23708000
-1.1%
-23461000
-222.3%
-7280000
+76.3%
-30696000
EPS (Basic)
$-1.45
-19.8%
$-1.21
-39.1%
$-0.87
-383.3%
$-0.18
+76.3%
$-0.76
EPS (Diluted)
$-1.45
-19.8%
$-1.21
-51.2%
$-0.80
-344.4%
$-0.18
+76.3%
$-0.76
Shares (Diluted)
19.8M
+0.9%
19.6M
-32.7%
29.2M
-28.2%
40.6M
+0.0%
40.6M
Keros Therapeutics (KROS) โ€” Financials